Abstract
The emergence of the United States Food and Drug Administration (FDA)-approved amyloid-targeting therapies for Alzheimer’s disease challenges clinicians and healthcare providers with a transformative landscape. Effectively communicating the risks, benefits, burdens, costs, and available support associated with these novel disease-modifying treatments to patients, families, and other healthcare providers is essential but complex. In response, the Alzheimer’s Association’s Clinical Meaningfulness Workgroup has proposed language surrounding treatment eligibility, benefits, amyloid-related imaging abnormalities (ARIA), apolipoprotein E (APOE) genotyping, and treatment costs, serving as a resource to healthcare professionals in navigating discussions with patients and their families. As the landscape evolves with the approval of new Alzheimer’s therapies, this resource stands poised for updates, ensuring its continued relevance in facilitating informed and meaningful patient-provider dialogues.
Highlights
Effective communication of risks, benefits, burdens, and costs of FDA-approved amyloid-targeting antibodies is essential to patients, families, and healthcare providers.
The Alzheimer’s Association’s Clinical Meaningfulness Workgroup provides language for physicians and healthcare providers around treatment eligibility, benefits, ARIA, APOE genotyping, and treatment costs.
This supplementary resource may be updated as new AD therapies become approved.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Dorene M. Rentz,
Paul S. Aisen,
Alireza Atri,
Janice Hitchcock,
Michael Irizarry,
Jaren Landen,
Brandy R. Matthews,
David S. Miller,
Simin Mahinrad,
Salvatore Napoli,
Hamid R. Okhravi,
Ronald C. Petersen,
Eric R. Siemers,
Christopher J. Weber,
David C. Weisman,
Maria C. Carrillo | September 22, 2024